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ABSTRACT 
The aim of this study was to evaluate the corneal safety, intraocular pressure (IOP), vault and refractive efficiency of 
the new implantable phakic contact lens, IPCL V2.0 (Care Group, India). A prospective case series study was 
performed to evaluate 100 consecutive surgeries with IPCL V2.0 (spherical and toric models). Refractive results, 
corneal endothelial cell density (CD) and central corneal thickness (CCT) were measured at baseline and 6 months 
after surgery. Intraocular pressure was measured at baseline, 1 day and 6 months, and vault, 3 and 6 months after 
surgery. Surgical complications and cataract development were also evaluated. The mean corneal endothelial CD 
decreased by 2.9% with a statistically significance difference (p: 0.03). The mean CCT decreased by 0.87% at 6 months 
postoperative, without a statistical significance difference (p: 0.35). The mean ± standard deviation (SD) of IOP at 
baseline was 13.72 ±1.4 mm Hg, at 1 day postoperative was 13.88 ±1.2 mm Hg, and at 6 months was 13.62 ±1.3 mm Hg. 
These differences were not statistically significant (p: 0.37). The difference in vault between 3 and 6 months after 
surgery was not statistically significant (p: 0.97). The coefficient of correlation between the attempted versus achieved 
spherical equivalent (SE) change was R2: 0.958. Postoperative SE was between -0.50 D to +0.50 D in 52% of cases. The 
remaining of the eyes had SE values ranging from -1.5 D to +1.35 D. No intra or postoperative complications occurred 
and specifically cataract was not developed. The corneal endothelial CD, CCT, vault and IOP remained stable 6 
months after surgery. Refraction was improved and the IPCL V 2.0 was implanted safely. 
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INTRODUCTION
In the 1990s, the laser procedures constituted a great 
innovation in refractive surgery [1, 2]. In addition, the 
cornea has demonstrated to be strong enough to resist 
manual intersections and incisions [3-5]. Photoablation 
refractive surgeries have become accessible and easy to 
perform for most surgeons worldwide, and these very 
quick procedures result in high efficiency [5]. However, 
as the knowledge of corneal biomechanics [6, 7]and 
optical aberrations [8, 9] increases, and new devices to 
evaluate both are now clinically available, surgeons are 
reconsidering refractive laser procedures to avoid 
complications such as postoperative ectasia, refractive 
regressions, high index aberration, corneal wound-
healing problems and ocular surface disease, e.g. dry eye 
and neuropathic pain [10-14]. Refractive surgery beyond 
laser technology has grown through intraocular lens 
development. The intraocular pseudo-phakic lens has a 
long history, but the phakic intraocular lens (PIOL) is 
more recent. The design and results of PIOL are still 
undergoing improvement [15-21].
 
They could be 
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implanted in the Anterior Chamber (AC) (iris fixated or 
angle supported) or at the posterior chamber. Both 
surgical procedures are reversible and provide 
maintenance of accommodation. However, this lens and 
its implantation procedures are associated with 
complications which are widely described [22-24]. Many 
studies have evaluated different models of PIOL (as 
Artisan, Artiflex, ICL) and only two papers [25, 26] exist 
about the implantable phakic contact lens called IPCL 
(Care Group, India). Nevertheless, there is a lack of 
scientific published information about the new model of 
IPCL (V 2.0). Therefore, the purpose of this work was to 
evaluate the safety and efficiency of implanting IPCL 
V2.0. 
METHODS 
Study Design 
A prospective case series study was performed to 
evaluate the safety and efficiency of 100 consecutive 
IPCL surgeries. This longitudinal study began in 
November 2017 and conducted in accordance with the 
Declaration of Helsinki with the approval of “Clinica de 
Ojos Dr. Nano” Institutional Review Board/Ethics 
Committee. Patients were informed about the study 
characteristics, their possible risks and a written 
informed consent was obtained before the procedures. 
Inclusion/Exclusion Criteria 
Inclusion criteria: Patients with myopia, when corneal 
refractive surgery could be contraindicated (thin corneas, 
severe dry eye) and, with stable refraction for a 
minimum period of one year. 
Exclusion criteria: Patients with less than a corneal 
endothelial cell density (CD) 2000 cell/mm
2
; anterior 
chamber depth (ACD) less than 2.8 millimetres (mm); a 
history of glaucoma and or glaucoma or retinal surgery. 
In the present series, patients with hypermetropia were 
also excluded. 
IPCL Characteristics 
The IPCL is a hydrophilic acrylic, single-piece, posterior 
chamber PIOL. It is foldable, injectable and designed to 
be implanted behind the iris with the haptic zone resting 
on the ciliary sulcus, delivery directly through 2.8 mm 
corneal incision. Its design includes 6 haptics to increase 
stability, 2 holes in the peripheral portion from the upper 
zone and 4 holes outside the optical zone to facilitate 
their loading in the cartridge and unfolding inside the 
eye, placing the anterior side of the lens facing upwards. 
The V 2.0 has an extra central conic hole (380 
micrometers [µm]) designed to minimize scattering and 
glare and facilitate its alignment and aqueous humour 
circulation. The previous iridotomy with the IPCL V2.0 is 
not necessary. Its dioptric power range is designed to 
correct myopia from -1.00 to -30.00 Diopters (D) and 
hypermetropia from +1.0 to +15.0 D. It was developed 
with an aspheric optic zone, with zero aberration. The 
optic diameter range is from 5.75 to 6.20 mm and the 
overall diameter is from 11.0 mm to 14.00 mm (with 0.25 
mm steps). Moreover, the optical diameter is 6.60 mm 
which could be customized up to 7.25 mm, according to 
the pupil size of patient. Data is available from the 
Official Brochure of the lens, available from Care Group; 
(http://caregroupiol.com/products/phakic-lenses/ipcl/). 
 
Preoperative Studies and Parameters to Evaluate 
At baseline (one week preoperative), all the patients 
underwent a complete ophthalmic examination. The 
population information regarding age and gender was 
registered. The Pentacam imaging system (Oculus, 
Wetzlar, Germany) was used for preoperative evaluation 
of the cornea (to detect regular versus (vs.) irregular 
astigmatism) and to measure the ACD, which is the 
distance from the corneal endothelium to the anterior 
surface of the lens. The preoperative determination of 
IPCL lens size was based on the horizontal white-to-white 
distance (using the IOL-Master equipment). The target 
was emmetropia in all cases and objective (spherical and 
cylinder) refraction was evaluated before and 6 months 
after surgery.  
Preoperatively, the corneal endothelial cell density (CD) 
and central corneal thickness (CCT) were registered and 
then, 6 months after the operation, using an electronic 
specular microscope (TOMEY EM4000). The intraocular 
pressure (IOP) was evaluated at baseline, 1 day and 6 
months after surgery (by Goldman tonometry). The IPCL 
vault was evaluated 3 and 6 months after surgery 
(performed with the ultra-biomicroscopy AvisoTM; 
Quantel Medical). The presence of intraoperative and/or 
postoperative complications was also evaluated, 
specifically to detect signs of cataract development (by 
slit lamp graded always by the same observer) according 
to The Lens Opacities Classification System III (LOCS III) 
classification.  
Descriptive statistical results were presented as mean, 
standard deviation (SD) and range. To compare the 
differences between the mean endothelial CD, CCT 
(baseline vs. 6 months postoperative) and vault (3 vs. 6 
months after surgery), paired sample t-test was 
performed. To compare the mean IOP (at baseline, 1 day 
and 6 months postoperative) ANOVA (single factor) was 
used. A statistically significant result was considered with 
a p-value less than 0.05. The coefficient of determination 
(R
2
) was calculated as part of the linear regression 
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analysis to evaluate the correlation between the 
attempted and achieved spherical equivalent (SE) 
change. Statistical analysis was performed with the 
XLMiner Analysis ToolPak software (Frontline Systems 
Inc.) 
Surgical Technique Description: Steps and Tips 
All of the surgeries were performed by the same surgeon 
(GB) and the use of viscoelastic substances was 
completely avoided. This is the routine surgical technique 
used by the surgeon to implant posterior chamber PIOLs 
and although it is not the specific objective of this study, 
some of its advantages were described in the discussion 
section.  
Steps 
Under topical anesthesia, a first corneal incision (located 
at 45 degrees) was performed with the 20 Gauge V-lance, 
and the AC was maintained with infusion/irrigation 
cannula (a 21 Gauge bi-manual Irrigation/Aspiration (I/A) 
cannula). A second corneal 2.8-mm incision was 
performed (located 130 degrees). 
Meanwhile, the AC was maintained with a balanced salt 
solution (BSS) fluid circulation, and the phakic lens was 
injected. The lens was unfolded softly with the aid of the 
I/A cannula, and the haptics was correctly placed behind 
the iris, into the sulcus, from 3 o'clock to 9 o'clock. 
Finally, an intracameral antibiotic (cefuroxime) was 
injected and the operation finished. 
Tips 
The BSS bottle must be elevated at 70 to 100 centimeters 
(cm) at all the time. A positive pressure into the AC must 
always be maintained and continuous BSS irrigation is 
required. 
The IPCL was previously charged in their delivery device 
without viscoelastic substances. The lens is pushed to the 
distal part of the device, leaving it ready to be injected 
into the eye. 
A toric lens is always placed between 0 and 180 degrees. 
Rotation is not needed, because astigmatism for each 
case came previously developed in the lens. The surgeon 
must be aware to mark the 0 to a 180-degree axis. The 
postoperative topical treatment was the same for all 
patients, starting three days before the operation with 
gatifloxacin 0.5% and bromfenac 0.09%, four times daily. 
Patients continued the treatment after the operation 
adding difluprednate 0.05% four times daily. All the 
drops were maintained for two weeks.  
RESULTS 
Among all of the operated cases, 8 surgeries were 
performed in only one eye (8 patients) and the other 92 
surgeries were performed at both eyes (46 patients; one 
eye first and the other was operated one week later). A 
total of 54 patients were operated (29 women and 25 
men). The mean ± SD of age was 29.7 ±7.5 years (range: 
23-55). The toric models were implanted at 39 eyes and 
the non-toric in 61 eyes. All the surgeries were 
performed without intraoperative complications. Post-
operative complications did not occur and 6 months after 
surgery, none of the eyes developed cataracts. 
Corneal Safety 
The mean corneal endothelial CD decreased by 2.9% with 
a statistically significance difference (P=0.03). The mean 
CCT decreased by 0.87% at 6 months after surgery, 
without a statistical significance difference P=0.35 
(complete data is shown in Table 1). 
Intraocular Pressure 
The IOP values remain similar at baseline and 1 day and 6 
months after surgery (Table 1). A slight increase was 
observed the first day post-operation, which decreased 
at the end of study, but the values were always in the 
normal IOP range. Moreover, there was no statistical 
significance difference between baseline, 1 day and 6 
months after surgery (P=0.37).  
Vault 
Statistical information regarding vault (3 months vs. 6 
months postoperative comparison) is presented in Table 
1. Results are very similar without statistically significant 
differences (P=0.97). Figs 1 and 2 show vaults data and 
their relation with ACD and the SE  refraction, 
respectively. The preoperative mean white-to-white 
value was 12.24 ±0.39 mm. The mean IPCL diameter was 
13.00 ±0.41 mm. The difference between white to white 
measurement and IPCL diameter was -0.76 ±0.20 mm.  
Efficiency: Spherical and Cylinder Refractive 
Results 
Fig 3 shows the SE refractive accuracy. In total, 52% of 
the eyes obtained SE between -0.5 to +0.5 D. (data 
obtained from dark blue columns sum is shown in the Fig 
3). The remaining eyes had SE values ranging from -1.5 D 
to +1.35 D. Fig 4 shows the coefficient of correlation (R
2
: 
0.958), which denotes the strength of the correlation 
between the attempted and achieved SE change. The 
pre-operative mean ± SD (range) spherical values were -
9.76 ±5.6 D (-2.25 to -22.0) and post-operative 0.04 ±0.52 
D (-0.75 to +1.25). Pre-operative mean ± SD (range) 
cylinder values were       -1.70 ±0.99 D (-4.25 to 0.00) and 
postoperative -0.63 ±0.25 D (-1.25 to 0.00). 
Fig 5 and 6 show pre- and postoperative spherical and 
cylinder evaluation, respectively (baseline and 6 months 
postoperative).  
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Table 1: The Mean Values from Endothelial Cell Density (CD), Central Corneal Thickness (CCT), Vault, and Intraocular Pressure (IOP), were presented 
and compared at Different Time-points. 
 Baseline Six months’ post-op P-value 
 Mean ± SD; (range) Mean ± SD; (range)  
Endothelial CD (cell/mm2) 2625.52 ±246.18; (1870-3115) 2549.09 ±248.89; (1850-3102) 0.03 
CCT (µm) 503.52 ±32.74; (400-576) 498.97 ±34.79; (397-595) 0.35 
 Three months post-op Six months post-op  
Vault (µm) 541.15 ±117,12; (305-890) 541.71 ±117.67; (305-890) 0.97 
 Baseline One day post-op Six months post-op  
IOP (mm Hg) 13.72 ±1.4; (11-16) 13.88 ±1.2; (11-16) 13.62 ±1.3; (12-16) 0.37 
SD: standard deviation; mm2: square millimetre; µm: micrometer; mmHg: millimetre of mercury; Post-op: postoperative. 
P-value less than 0.05 is in bold  
 
 
Figure 1: The Relation between the Vault (micrometer) and Anterior 
Chamber Depth (ACD) (millimeter). 
 
 
Figure 2: The Relation Between the Vault (micrometer) and the 
Spherical Equivalnt Refraction Result (D). D: diopter. 
 
Figure 3: Spherical Equivalent Refractive Accuracy. The percentage (%) 
of eyes related to their spherical equivalent achieved at 6 months 
after surgery. The dark blue columns are remarking the percentage of 
eyes with spherical equivalent refraction between +0.50 to -0.50; 
summarizing 52%. D: diopter; %: percentage. 
 
 
Figure 4: Spherical Equivalent Attempted Versus Achieved. The 
Correlation Between the Attempted and Achieved Spherical 
Equivalent (D) Change Is Shown With the Coefficient of Determination 
(R2). D: diopter. 
 
 
 
Med Hypothesis Discov Innov Ophthalmol. 2019; 8(2)  
 
61 POSTERIOR CHAMBER IMPLANTABLE PHAKIC CONTACT LENS: IPCL V2.0. 
 
Figure 5: Spherical Refraction (D): Baseline Versus 6 Months Post-
operative.  
D: diopter; Spherical POST: postopertative Spherical result; Spherical 
PRE: Preoperative Spherical result. 
 
 
Figure 6: Cylinder Refraction (D): Baseline Versus 6 Months Post-
operative. D: diopter; Cyl POST: postopertative cylinder result; Cyl 
PRE: Preoperative cylinder result. 
 
DISCUSSION 
The main findings of this study show that IPCL V2.0 has 
achieved expected refractive results, IOP and vault 
remained stable and corneal endothelial CD had no 
change 6 months after surgery.  
Refractive surface procedures using a laser are more 
frequently performed than intraocular procedures 
because it is postulated that they have fewer 
complications and also could be quicker and easy to 
perform. This is true when the right case is selected. 
However, obtaining independence from glasses is 
difficult to offer patients with high myopia or thin 
corneas, for whom laser corneal refractive procedures 
are not recommended because of the risk of 
complications. For this group of patients, PIOLs are a very 
good choice [15-21], as the present results showed. 
The PIOL preserves the accommodative function. The 
procedure is reversible and has the advantage to induce 
minimal higher-order aberrations compared to corneal 
refractive surgeries [27]. Since their introduction in 1986, 
posterior chamber PIOLs have been improved 
considerably [28], however, to date, there are no 
extensive studies of the IPCL, except for only two 
recently published papers, with the previous model, IPCL 
V1.0. In one of those studies, Vasavada V et al. [25] 
described three years’ follow-up of 30 eyes. They 
reported an endothelial cell loss of 9.73%, with good 
refractive results and without complications. Sachdev G 
et al. [26] followed 134 eyes during at least one year 
after IPCL V1.0 model was implanted. The authors 
concluded that IPCL is a safe and effective procedure for 
correction of myopia and myopic astigmatism. The 
present study had many differences with those studies 
regarding IPCL model, IOP, endothelial CD and CCT, vault 
and refractive result. Some aspects of the surgical 
technique would be described because this is another 
difference with previous IPCL published studies. 
The IPCL platform has had changes between V 1.0 and V 
2.0 models. In the present study, the new IPCL V 2.0 
model was specifically evaluated through a hundred 
consecutive procedures. The author of this work has a 
large experience and good results with the previous IPCL 
model V 1.0, since 2015. For this model, pre-operative 
iridotomy was always performed to prevent 
postoperative pupillary blockage and IOP rise. With IPCL 
V 2.0 it was not necessary to perform the iridotomy. And 
as seen for the results of the present series, the IOP 
remained stable in all cases, 1 day and 6 months after 
surgery. It is necessary to remark that the surgical 
technique for this study was performed by completely 
avoiding the use of viscoelastic substance. Therefore, this 
surgical method perhaps has an “extra value” to avoid 
the potential IOP peak after surgery associated with a 
deficiency viscoelastic extraction [28, 29]. 
Is it possible to work safely inside the AC without 
viscoelastic substance avoiding endothelial corneal 
damage? The author of this work has a long experience 
performing phacoemulsification cataract surgery without 
viscoelastic substance (a technique called Bianchi’s 
method) [30, 31].
  
In this work, 6 months after surgery 
the corneal endothelial CD decrease was 2.9%. Even 
though the difference was statistically significant, the 
procedure seems to provide very good value compared 
to the literature reference and there was no statistically 
significant difference in CCT 6 months after surgery 
compared to the baseline. Similar results have been 
published by Sachdev et al. [26] performing a surgical 
technique with viscoelastic substance (endothelial CD 
loss was 2.01% one year after surgery). This information 
supports the conclusion that IPCL and the present 
surgical technique was safe for corneal tissue.  
The posterior chamber PIOL is designed to be placed on 
the sulcus, behind the iris and in front of the anterior 
capsule of the crystalline lens. The central vault is the 
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distance between the posterior surface of the IPCL and 
anterior surfaces of the crystalline lens. Several problems 
could arise if the IPCL size (diameter) is not correctively 
selected, according to the sulcus length, obtained by 
biometry of the eye. Because lower vault has a major risk 
to develop cataracts. So, the vault is an important safety 
parameter which also is related to refractive outcome. A 
secure vault value was considered to be between 250 to 
750 µm and when it was close to 1000 µm the lens must 
be explanted [16, 24]. In this study, only 3 cases 
presented a vault higher than 750 µm in eyes with a deep 
AC (higher than 3 mm). The mean vault value observed in 
the present study was stable over time, without a 
statistically significant difference between 3 to 6 months 
follow-up. These data emphasize the postoperative 
stability and security of IPCL (as none of the cases 
developed cataracts).  
In the present study, the difference between white-to-
white measurement and IPCL diameter was -0.76 ±0.20 
mm. A correct selection of the adequate PIOL size is 
relevant and directly related to predicting the proper 
amount of PIOL vault, which is considered to be identical 
to the thickness of the central cornea (approximately 500 
µm) in each case. Implantable phakic contact lens size 
changes in steps of 0.25 mm, and appropriate size is 
selected based on the horizontal corneal diameter and 
ACD. Good results may also be secondary to the “V 2.0 
spring effect” due to their design. The refractive efficacy 
was demonstrated by the spherical and cylinder decrease 
after surgery. The expected refractive results have been 
effectively achieved.  
Another similar posterior chamber PIOL exists. Packer M. 
[32] has published an extensive review of literature 
about the Implantable Collamer Lens (ICL) with a central 
port called “ICL EVO V4c” (STAAR Surgical, Inc.) and he 
concluded that this lens is an attractive option for 
surgeons and patients, with high levels of refractive 
predictability, stability and safety results. Implantable 
phakic contact lens is a more recent option, with the 
same surgical indications as ICL EVO V4c. There is a lack 
of literature to compare IPCL with ICL yet and until the 
time of the present study, only 3 papers were published 
in indexed journals, about IPCL results. Further 
comparative studies are interesting to evaluate both 
lenses. 
One limitation of the present work is that only one 
surgeon performed a particular surgical technique. 
Another aspect that must be considered is about the 
follow-up time. In the present study, results were 
evaluated at 6 months, which is a short time. But this is 
the first study reporting results with this lens and this 
data could be useful in future studies. Further studies 
with IPCL by other surgeons and longer follow-up are 
necessary to confirm the present results. Also, a 
prospective cohort multicentric study comparing the 
present technique with surgeries performed with 
viscoelastic substance is useful to confirm this specific 
surgical aspect.  
CONCLUSIONS 
This work evaluated IPCL results after 100 consecutive 
surgeries that completed 6 months follow-up, since 
November 2017. Regarding the surgical technique, even 
so, it was not the objective of this study, it was detailed 
described because results could be influenced by that. It 
is a personal technique, which could be useful for other 
surgeons, and this is another original aspect of this study. 
Findings showed that the endothelium and CCT were not 
affected 6 months after IPCL implantation, completely 
avoiding viscoelastic substances. The postoperative IOP 
did not increase after surgery. Vault remained stable, 
within safe parameters 3 and 6 months after surgery and 
cataract did not develop. The postoperative refraction 
achieved was good enough and aligned with the 
preoperative expectations for both spherical and cylinder 
(spherical and toric models).  
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